← Back to Search

Repeat Surgery for Recurrent Glioblastoma

Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Previously histologically confirmed and surgically resected Glioblastoma
Previous craniotomy for open tumor resection (needle biopsies alone do not count as resection)
Screening 3 weeks
Treatment Varies
Follow Up follow-up for 5 years or until death
Awards & highlights

Study Summary

This trial is important because it will help neurosurgeons manage patients with recurrent GBM in the best way possible.

Who is the study for?
This trial is for adults over 18 with recurrent Glioblastoma (GBM) who've had it surgically removed before. Candidates should be considered by their surgeon to potentially benefit in quality of life from another surgery. Those unable to give informed consent are excluded.Check my eligibility
What is being tested?
The study tests the effectiveness of repeat surgical resection on patients with recurrent GBM, aiming to see if a second surgery can extend overall survival and improve time spent out of hospitals or care facilities without extra risks beyond standard care.See study design
What are the potential side effects?
Since the intervention involves routine surgical procedures, potential side effects include typical surgical risks such as infection, bleeding, neurological deficits depending on tumor location, and general anesthesia complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
My glioblastoma was confirmed by a biopsy and has been surgically removed.
I have had brain surgery to remove a tumor.
I am 18 years old or older.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~follow-up for 5 years or until death
This trial's timeline: 3 weeks for screening, Varies for treatment, and follow-up for 5 years or until death for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Length of Overall Survival
Secondary outcome measures
Discharge to a location other than home
Incidence of peri-operative non-neurological complications (wound infection, CSF leaks)
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Repeat Surgical ResectionExperimental Treatment1 Intervention
Standard surgical operative management according to local practices.
Group II: Management Without Re-operationActive Control1 Intervention
Non-surgical management with standard care according to local practices.

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
889 Previous Clinical Trials
384,888 Total Patients Enrolled
1 Trials studying Glioblastoma
40 Patients Enrolled for Glioblastoma

Media Library

Repeat Surgical Management of Recurrent GBM Clinical Trial Eligibility Overview. Trial Name: NCT04838782 — N/A
Glioblastoma Research Study Groups: Repeat Surgical Resection, Management Without Re-operation
Glioblastoma Clinical Trial 2023: Repeat Surgical Management of Recurrent GBM Highlights & Side Effects. Trial Name: NCT04838782 — N/A
Repeat Surgical Management of Recurrent GBM 2023 Treatment Timeline for Medical Study. Trial Name: NCT04838782 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have enrolled in this research project thus far?

"Affirmative. The clinical trial is still recruiting according to the information published on clinicaltrials.gov, which was first posted in late August 2021 and last revised on April 5th 2022. Approximately 250 volunteers are sought for this single-site research project."

Answered by AI

Is recruitment still underway for this research initiative?

"Clinicaltrials.gov confirms that the recruitment process for this medical study is ongoing, having been first posted on August 26th 2021 and last updated on April 5th 2022."

Answered by AI
Recent research and studies
~167 spots leftby Jan 2030